Clinical trial

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

NCT05441488

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Masitinib (4.5) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Design: INTERVENTIONAL · Status: SUSPENDED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusSUSPENDED

Study typeINTERVENTIONAL

Start date2022-06-28

PhasePHASE3

Conditions

Progressive Multiple Sclerosisunresolved

Interventions

PlaceboDRUG

Masitinib (4.5)DRUG

Sponsors & collaborators

AB Sciencelead sponsor

Mapped research locations

MadridSpain2 Saint PetersburgRussia2 AthensGreece2 BarcelonaSpain1 MoscowRussia1 WarsawPoland1 ValenciaSpain1 ToulouseFrance1 StrasbourgFrance1 LilleFrance1 StockholmSweden1 PoznanPoland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05441488 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.